NCT03286556: A trial that was reported late by University of Alabama at Birmingham
This trial has reported, although it was 34 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03286556 |
|---|---|
| Title | Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 4, 2018 |
| Completion date | Aug. 1, 2024 |
| Required reporting date | Aug. 1, 2025, midnight |
| Actual reporting date | Sept. 4, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 34 |